Drug intelligence / Profile preview

nivolumab + GX-188E + GX-I7

Development stage: Unknown
Lead developer: Genexine
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Intramuscular

Overview

A triple combination therapy consisting of nivolumab (a PD-1 immune checkpoint inhibitor), GX-188E (tirvalimogene teraplasmid, a therapeutic DNA vaccine targeting HPV-16 and HPV-18), and GX-I7 (efineptakin alfa, a long-acting recombinant human interleukin-7). This combination is designed to enhance anti-tumor immune responses in HPV-positive cancers by combining checkpoint inhibition with a targeted DNA vaccine and T-cell amplification.

Targets

HPV18 E6 (HPV18 E6 protein)IL7R (Interleukin-7 Receptor)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on nivolumab + GX-188E + GX-I7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nivolumab + GX-188E + GX-I7.

Explore the full profile